A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age
Phase of Trial: Phase I/II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs JNJ 64400141 (Primary) ; Meningococcal vaccine groups A B C Y W-135 conjugate
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Janssen Vaccines and Prevention B.V
- 30 Sep 2019 Planned End Date changed from 14 May 2021 to 31 Oct 2021.
- 08 Aug 2019 This trial has been discontinued in Germany, according to European Clinical Trials Database
- 10 Jul 2019 Status changed from active, no longer recruiting to recruiting.